Wire · opportunities
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
Johnson & Johnson's RYBREVANT (amivantamab-vmjw) plus chemotherapy significantly extended median overall survival to 34.3 months versus 27.9 months with chemotherapy alone in patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer, marking the longest reported survival in this difficult-to-treat population.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must reset survival expectations for EGFR exon 20 insertion lung cancer and position RYBREVANT plus chemotherapy as the new standard for treatment first-line. The advantage in overall survival creates a strong clinical differentiation you can use to engage oncologists and patients.
◆ Coverage
1 source · 14 Sep 2026
◆ Related on Wire
◆ Topics